deferoxamine has been researched along with Alveolitis, Fibrosing in 11 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 7.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "Eight patients with transfusion-dependent thalassemia major were given continuous intravenous infusions of the chelator, deferoxamine mesylate, to reduce iron overload." | 3.68 | Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. ( Freedman, MH; Grisaru, D; MacLusky, I; Olivieri, N; Thorner, PS, 1990) |
| "However, its role in pulmonary fibrosis, a fatal lung disease with unknown etiology, is largely unknown." | 1.62 | Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis. ( Cheng, H; Feng, D; Gao, L; Li, C; Li, X; Liu, W; Luo, Z; Tang, S; Wu, X; Yue, S, 2021) |
| "Deferoxamine pretreatment and daily injections resulted in a significant reduction in lung collagen content and lung lipid peroxidation 21 days after intratracheal bleomycin compared with bleomycin treatment alone." | 1.27 | Modulation of the development of bleomycin-induced fibrosis by deferoxamine. ( Barton, JC; Briggs, DD; Butler, TW; Chandler, DB; Fulmer, JD; Grizzle, WE, 1988) |
| "Deferoxamine pretreatment and daily injection for 21 days after intratracheally administered bleomycin resulted in a 33% reduction in lung collagen accumulation compared with that after bleomycin treatment alone." | 1.27 | The effect of deferoxamine on bleomycin-induced lung fibrosis in the hamster. ( Chandler, DB; Fulmer, JD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (54.55) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H | 1 |
| Feng, D | 1 |
| Li, X | 1 |
| Gao, L | 1 |
| Tang, S | 1 |
| Liu, W | 1 |
| Wu, X | 1 |
| Yue, S | 1 |
| Li, C | 1 |
| Luo, Z | 1 |
| Jack, CI | 1 |
| Jackson, MJ | 1 |
| Johnston, ID | 1 |
| Hind, CR | 1 |
| Kim, KA | 1 |
| Park, CY | 1 |
| Lim, Y | 1 |
| Lee, KH | 1 |
| Castriota Scanderbeg, A | 1 |
| Izzi, GC | 1 |
| Butturini, A | 1 |
| Benaglia, G | 1 |
| Freedman, MH | 2 |
| Grisaru, D | 1 |
| Olivieri, N | 1 |
| MacLusky, I | 1 |
| Thorner, PS | 1 |
| Cross, CE | 1 |
| Warren, D | 1 |
| Gerriets, JE | 1 |
| Wilson, DW | 1 |
| Halliwell, B | 1 |
| Last, JA | 1 |
| Kennedy, JI | 1 |
| Chandler, DB | 3 |
| Jackson, RM | 1 |
| Fulmer, JD | 3 |
| Butler, TW | 1 |
| Briggs, DD | 1 |
| Grizzle, WE | 1 |
| Barton, JC | 1 |
| Ward, HE | 1 |
| Hicks, M | 1 |
| Nicholson, A | 1 |
| Berend, N | 1 |
| Bentur, Y | 1 |
| Koren, G | 1 |
2 reviews available for deferoxamine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Recent advances in particulate-induced pulmonary fibrosis; for the application of possible strategy experimentally and clinically.
Topics: Adrenal Cortex Hormones; Animals; Antioxidants; Blood Proteins; Chelating Agents; Cytokines; Deferox | 2000 |
Biological and toxic properties of deferoxamine.
Topics: Cataract; Cell Division; Deferoxamine; DNA; Drug Hypersensitivity; Hearing Disorders; Humans; Pulmon | 1989 |
9 other studies available for deferoxamine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Iron deposition-induced ferroptosis in alveolar type II cells promotes the development of pulmonary fibrosis.
Topics: Animals; Bleomycin; Cation Transport Proteins; Deferoxamine; Disease Models, Animal; Ferroptosis; Ge | 2021 |
Serum indicators of free radical activity in idiopathic pulmonary fibrosis.
Topics: Aged; Antibodies, Antinuclear; C-Reactive Protein; Deferoxamine; Disease Progression; Female; Free R | 1996 |
Pulmonary syndrome and intravenous high-dose desferrioxamine.
Topics: Adolescent; Child; Deferoxamine; Humans; Infusions, Intravenous; Pulmonary Fibrosis; Thalassemia | 1990 |
Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Drug Hypersensitivity; Female; Humans; Imm | 1990 |
Deferoxamine injection does not affect bleomycin-induced lung fibrosis in rats.
Topics: Animals; Bleomycin; Body Weight; Collagen; Deferoxamine; Lung; Male; Organ Size; Pulmonary Fibrosis; | 1985 |
Reduction in bleomycin-induced lung hydroxyproline content by an iron chelating agent.
Topics: Animals; Bleomycin; Chelating Agents; Cricetinae; Deferoxamine; Hydroxyproline; Iron; Lung; Male; Me | 1986 |
Modulation of the development of bleomycin-induced fibrosis by deferoxamine.
Topics: Animals; Bleomycin; Collagen; Cricetinae; Deferoxamine; Hydroxides; Hydroxyl Radical; Lipid Peroxide | 1988 |
Deferoxamine infusion does not inhibit bleomycin-induced lung damage in the rat.
Topics: Animals; Bleomycin; Deferoxamine; Infusion Pumps; Iron; Lung; Lung Diseases; Osmolar Concentration; | 1988 |
The effect of deferoxamine on bleomycin-induced lung fibrosis in the hamster.
Topics: Animals; Bleomycin; Collagen; Cricetinae; Deferoxamine; Lung; Lymphocytes; Male; Mesocricetus; Pulmo | 1985 |